Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome's first commercial-stage test, SimpleScreen CRC for colorectal cancer, is under review by the U.S. Food and Drug Administration (FDA).
Subscribe to see Freenome’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Freenome is a biotech company headquartered in Brisbane, United States. It is publicly listed (FRNM) with a market capitalisation of $130.6M. Xcout tracks 18 named people at Freenome, including Aaron Elliott (CEO & Director). Xcout recorded 47 job postings from Freenome in the last 90 days, naming tools such as PyTorch, TensorFlow, MLflow.
12 more named people on record for Freenome, with roles, board committees and tenure — see the full roster →
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $65M | 8 named | |
| Seed | $5.5M | 1 named |
Some filings are not shown as funding rounds.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Xcout recorded 47 job postings from Freenome in the last 90 days, from a hiring record Xcout has kept since July 2026.
The weekly hiring trend, the roles and locations behind it — see Freenome's hiring signals →
3 corporate events on record, with sources — see the full timeline →
A few of Freenome's closest competitors — see the full list of competitors and alternatives →
GRAIL, Inc. is an innovative commercial-stage healthcare and life sciences company headquartered in Menlo Park, California, focused on early cancer detection technologies. The company was acquired by Illumina in 2021.
Precede Biosciences is a biotechnology company developing blood-based liquid-biopsy technologies for molecular profiling of cancer. Its tests are intended to support oncology research, precision treatment decisions, and pharmaceutical drug-development programs.
Adela, Inc. is an epigenomics-focused biotechnology company headquartered in Foster City, California. The company is advancing breakthrough approaches for the early detection of multiple types of cancer through blood tests.
Nexosome Oncology Holdings, Inc. develops blood tests for early-stage cancer detection using patented extracellular vesicle proteomics and AI/ML biomarker discovery. The company serves patients and healthcare partners by providing highly accurate diagnostic tools.
SAGA Diagnostics provides ultra-sensitive, blood-based molecular residual disease (MRD) detection and monitoring tests for cancer patients. The company's flagship platform, Pathlight, uses tumor whole-genome sequencing and personalized digital PCR assays to detect circulating tumor DNA, primarily serving clinicians and biopharmaceutical partners for early cancer detection and treatment tracking.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Freenome? Suggest a correction
Post the link and the card appears automatically — each network fetches the image itself.